Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CTIX Now the rally is strengthened by numerous factors.
A key near-term catalyst is fast approaching with Brilacidin PIIb results. Cellceutix's Antibiotic Brilacidin Should Move Share Price Before Kevetrin Or Prurisol
This pre-catalyst buying volume and rally, suggests to seasoned investors that news is out that the Brilacidin 2b trial was successful.
We have word that there are many in the medical and scientific community very excited about Brilacidin-OM Phase 2B trial expected to start in 1 or 2 months
New Clinical Trial start catalysts are approaching for three drugs, Prurisol Phase 2/3 for Psoriasis, Kevetrin 1b for Leukemia(AML), Brilacidin OM phase 2B.
Up-listing plans, financing already in place for up-coming trials, and strong possibility of a partnership on positive Brilacidin PIIb results. Link to CTIX 10-K
Flagship cancer drug Kevetrin is at a high dose, well past the dosing level range believed therapeutic, and an almost certain successful clinical trial primary outcome of safety.
A rally wave continuation, or a third rally wave up to blue-sky territory is likely.
On positive Brilacidin PIIb trial results, all technical chart bets are off. News trumps charts.
Awesome 10K http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's CTIX, Awesome 10K, up listing, multiple trial results for revolutionary drugs soon, pps smoking hot, nearing all time high, possible partnership hinted at in 10K. LONG-TERM MULTI BAGGER.
CTIX screaming since 10K release Monday. Long term MONSTER.Up listing..eom
CTIX, up 35% recently. Nearing breakout territory..eom
CTIX, MONSTER BIO in the the making...eom
OTC's CTIX, HUGE 10K report, BREAKOUT in progress. LONG TERM MONSTER
OTC's CTIX Awesome 10K report yesterday. Breakout today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX breaks out since 10K release. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's. CTIX Awesome 10K yesterday,Breakout today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Yes, a nice day but only the beginning. They have a major results on their antibiotic trial in a matter weeks besides the other drugs in their pipeline. They announced a uplisting from the OTC's, they are hinting at a partnership. They are financially set till 2016 without a partnership. The 10k explains it all. LONG TERM HOLD.
The next 3-5 years will be very interesting and I believe financially liberating.
Have a great day
OTC's CTIX big time 10K report yesterday. Breakout today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's CTIX Awesome 10K report yesterday. Breakout today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX. The REAL DEAL. Awesome 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's CTIX. long term multibagger. GREAT 10K report yesterday. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX. long term monster. GREAT 10K report yesterday. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
OTC's CTIX Awesome 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX. 10K report today.WOW http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Otc, CTIX. Incredible 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX. Monster 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX. Awesome 10K report today. http://www.sec.gov/Archives/edgar/data/1355250/000147793214005027/ctix_10k.htm
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
CTIX recent news/filings/charts etc.
## source: finance.yahoo.com
Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in ...
read full: http://finance.yahoo.com/news/cellceutix-completes-enrollment-phase-2b-123000703.html
*********************************************************
$CTIX charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CTIX company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CTIX/company-info
Ticker: $CTIX
OTC Market Place: OTCQB
CIK code: 0001355250
Company name: Cellceutix Corp.
Company website: http://www.cellceutix.com
Incorporated In: NV, USA
Business Description: An early stage developmental biopharmaceutical company...with six pharmaceutical compound candidates that are designed for treatment of diseases which may be either existing or diseases identified in the future. The Company will initially spend most of its efforts and resources on its anti-cancer compound, Kevetrin, for the treatment of head and neck cancers.
$CTIX share structure
## source: otcmarkets.com
Market Value: $225,776,700 a/o Sep 12, 2014
Shares Outstanding: 108,027,129 a/o May 07, 2014
Float: Not Available
Authorized Shares: 300,000,000 a/o May 12, 2008
CTIX...Tue, 09 Sep 2014 19:00:00 GMT ~ Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently ...
read full: http://finance.yahoo.com/news/cellceutix-provides-initial-observations-completed-190000867.html
*********************************************************
Fri, 05 Sep 2014 15:15:46 GMT ~ Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be ...
read full: http://finance.yahoo.com/news/cellceutix-present-rodman-renshaws-16th-151546102.html
*********************************************************
Tue, 02 Sep 2014 11:00:00 GMT ~ Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. ...
read full: http://finance.yahoo.com/news/cellceutix-appoints-dr-barry-schechter-110000360.html
*********************************************************
Tue, 02 Sep 2014 10:29:26 GMT ~ CELLCEUTIX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements and
read full: http://biz.yahoo.com/e/140902/ctix8-k.html
*********************************************************
Tue, 19 Aug 2014 12:30:00 GMT ~ Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
[Marketwired] - Cellceutix Corporation , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in ...
read full: http://finance.yahoo.com/news/cellceutix-completes-enrollment-phase-2b-123000703.html
*********************************************************
CTIX, long term play. Uplisting in works
CTIX , looking to up list from Otc.
CTIX, CEO looking to up list. Volume at yearly high.eom
Otc, CTIX. Yearly high on great volume. Uplisting in works..eom
Otc, CTIX. Looking to uplist
Otc CTIX up listing, potential long term monster
CTIX up listing plus big volume at yearly high
Otc CTIX , big time long term potential with up listing.
CTIX. Big volume at yearly high.
Big long term potential. CTIX uplisting.http://cellceutix.com/#sthash.U82FK7sU.5O0rwcVG.dpbs
OTC "CTIX" uplisting in progress. http://cellceutix.com/#sthash.U82FK7sU.5O0rwcVG.dpbs
CTIX easy 10 bagger + long term
http://cellceutix.com/#sthash.U82FK7sU.JK0lqkBC.dpbs
3 years from now CTIX will be proudly displayed on your board.
http://cellceutix.com/#sthash.U82FK7sU.dpbs
BTW, GOOG and ATRO are fine companies to invest in.
Have a great weekend
Monster in the making.CTIX at 2.09
CTIX. 2.09 hitting yearly high on good volume.
CTIX chart looks good at at yearly high.
OTC CTIX 2.08 Do your DD and see the potential long term gains to be made.
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix has submitted an IND to the FDA for its planned Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, has completed enrollment in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than most currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.
OTC CTIX is looking to uplist. Long term monster in the making.
About Cellceutix:
Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol "CTIX". Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Cellceutix believes it has a world-class portfolio of compounds and is now engaged in advancing its compounds and seeking strategic partnerships. Cellceutix's anti-cancer drug Kevetrin is currently in a Phase 1 clinical trial at Harvard Cancer Centers' Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. In the laboratory Kevetrin has shown to induce activation of p53, often referred to as the "Guardian Angel Gene" due to its crucial role in controlling cell mutations. Cellceutix has submitted an IND to the FDA for its planned Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention and treatment of Oral Mucositis. Brilacidin-OM, a defensin mimetic compound, has shown in the laboratory to reduce the occurrence of severe ulcerative oral mucositis by more than 94% compared to placebo. Cellceutix's anti-psoriasis drug Prurisol has recently completed a Phase 1 clinical trial and is being readied for a Phase 2 trial. Prurisol is a small molecule that acts through immune modulation and PRINS reduction. Cellceutix's key antibiotic, Brilacidin, has completed enrollment in a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infections, or ABSSSI. Brilacidin has the potential to be a single-dose therapy or a dosing regimen that is shorter than most currently marketed antibiotics for multi-drug resistant bacteria (Superbugs). Cellceutix has formed research collaborations with world-renowned research institutions in the United States and Europe, including MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, and the University of Bologna. More information is available on the Cellceutix web site at www.cellceutix.com.